Drug Detail:Shingrix vaccine (Zoster vaccine (inactivated) [ zos-ter-vax-een ])
Generic Name: RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN 50ug in 0.5mL;
Dosage Form: suspension for intramuscular injection
Drug Class: Viral vaccines
Drug Detail:Shingrix vaccine (Zoster vaccine (inactivated) [ zos-ter-vax-een ])
Generic Name: RECOMBINANT VARICELLA ZOSTER VIRUS GLYCOPROTEIN E ANTIGEN 50ug in 0.5mL;
Dosage Form: suspension for intramuscular injection
Drug Class: Viral vaccines
For intramuscular injection only.
SHINGRIX is supplied in 2 vials that must be combined prior to administration. Prepare SHINGRIX by reconstituting the lyophilized varicella zoster virus glycoprotein E (gE) antigen component (powder) with the accompanying AS01B adjuvant suspension component (liquid). Use only the supplied adjuvant suspension component (liquid) for reconstitution. The reconstituted vaccine should be an opalescent, colorless to pale brownish liquid. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If either of these conditions exists, the vaccine should not be administered.
For intramuscular injection only.
After reconstitution, administer SHINGRIX immediately or store refrigerated between 2° and 8°C (36° and 46°F) and use within 6 hours. Discard reconstituted vaccine if not used within 6 hours.
Use a separate sterile needle and sterile syringe for each individual. The preferred site for intramuscular injection is the deltoid region of the upper arm.
Two doses (0.5 mL each) administered intramuscularly according to the following schedules:
• A first dose at Month 0 followed by a second dose administered 2 to 6 months later.
• For individuals who are or will be immunodeficient or immunosuppressed and who would benefit from a shorter vaccination schedule: A first dose at Month 0 followed by a second dose administered 1 to 2 months later.